A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers
Status:
Completed
Trial end date:
2007-09-18
Target enrollment:
Participant gender:
Summary
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
duration of action of GSK573719 when administered via inhalation in animal models supports
the potential for use as a once-daily bronchodilator for COPD